Hepatitis C Treatment with First-Generation Protease Inhibitors in A Real-World Cohort- Risk-Benefit Profile and Costs of the Therapy
Nov 1, 2016, 00:00 AM
10.1016/j.jval.2016.09.954
https://www.valueinhealthjournal.com/article/S1098-3015(16)32320-8/fulltext
Section Title :
Disease-Specific Studies
Section Order :
898
First Page :
A511
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32320-8&doi=10.1016/j.jval.2016.09.954